4,200
edits
Secretariat (talk | contribs) |
mNo edit summary |
||
Line 39: | Line 39: | ||
</ul> | </ul> | ||
|} | |} | ||
In 2009 | In 2009 these criteria were updated<cite>cox</cite>, see the table below. | ||
'''Treatment''' focuses on avoiding complications.<cite>ACC2006</cite> | '''Treatment''' focuses on avoiding complications.<cite>ACC2006</cite> | ||
Line 58: | Line 55: | ||
</gallery> | </gallery> | ||
== | == Revised Task Force Criteria ARVD / ARVC== | ||
{| class="wikitable" | {| class="wikitable" | ||
|+ | |+ Comparison of Original and Revised Task Force Criteria | ||
! style="width:500px" | Original Task Force Criteria | ! style="width:500px" | Original Task Force Criteria | ||
! style="width:500px" | Revised Task Force Criteria | ! style="width:500px" | Revised Task Force Criteria | ||
|- | |- | ||
| colspan="2" | I. Global or regional dysfunction and structural alterations<sup>∗</sup> | | colspan="2" | '''I. Global or regional dysfunction and structural alterations<sup>∗</sup>''' | ||
|- | |- | ||
| colspan="2" style="padding-left:12px" | Major | | colspan="2" style="padding-left:12px" | '''Major''' | ||
|- | |- | ||
| valign="top" style="padding-left:24px" | | | valign="top" style="padding-left:24px" | | ||
Line 87: | Line 84: | ||
* Regional RV akinesia, dyskinesia, or aneurysm | * Regional RV akinesia, dyskinesia, or aneurysm | ||
|- | |- | ||
| colspan="2" style="padding-left:12px" | Minor | | colspan="2" style="padding-left:12px" | '''Minor''' | ||
|- | |- | ||
| valign="top" style="padding-left:24px" | | | valign="top" style="padding-left:24px" | | ||
Line 106: | Line 103: | ||
** <em>or</em> RV ejection fraction >40% to ≤45% | ** <em>or</em> RV ejection fraction >40% to ≤45% | ||
|- | |- | ||
| colspan="2" | II. Tissue characterization of wall | | colspan="2" | '''II. Tissue characterization of wall''' | ||
|- | |- | ||
| colspan="2" style="padding-left:12px" | Major | | colspan="2" style="padding-left:12px" | '''Major''' | ||
|- | |- | ||
| valign="top" style="padding-left:24px" | | | valign="top" style="padding-left:24px" | | ||
Line 121: | Line 118: | ||
* Residual myocytes 60% to 75% by morphometric analysis (or 50% to 65% if estimated), with fibrous replacement of the RV free wall myocardium in ≥1 sample, with or without fatty replacement of tissue on endomyocardial biopsy | * Residual myocytes 60% to 75% by morphometric analysis (or 50% to 65% if estimated), with fibrous replacement of the RV free wall myocardium in ≥1 sample, with or without fatty replacement of tissue on endomyocardial biopsy | ||
|- | |- | ||
| colspan="2" | III. Repolarization abnormalities | | colspan="2" | '''III. Repolarization abnormalities''' | ||
|- | |- | ||
| colspan="2" style="padding-left:12px" | Major | | colspan="2" style="padding-left:12px" | '''Major''' | ||
|- | |- | ||
| | | | ||
Line 157: | Line 154: | ||
* Terminal activation duration of QRS ≥55 ms measured from the nadir of the S wave to the end of the QRS, including R´, in V<sub>1</sub>, V<sub>2</sub>, or V<sub>3</sub>, in the absence of complete right bundle-branch block | * Terminal activation duration of QRS ≥55 ms measured from the nadir of the S wave to the end of the QRS, including R´, in V<sub>1</sub>, V<sub>2</sub>, or V<sub>3</sub>, in the absence of complete right bundle-branch block | ||
|- | |- | ||
| colspan="2" | V. Arrhythmias | | colspan="2" | '''V. Arrhythmias''' | ||
|- | |- | ||
| colspan="2" style="padding-left:12px" | Major | | colspan="2" style="padding-left:12px" | '''Major''' | ||
|- | |- | ||
| | | | ||
Line 174: | Line 171: | ||
* >500 ventricular extrasystoles per 24 hours (Holter) | * >500 ventricular extrasystoles per 24 hours (Holter) | ||
|- | |- | ||
| colspan="2" | VI. Family history | | colspan="2" | '''VI. Family history''' | ||
|- | |- | ||
| colspan="2" style="padding-left:12px" | Major | | colspan="2" style="padding-left:12px" | '''Major''' | ||
|- | |- | ||
| style="padding-left:24px" valign="top" | | | style="padding-left:24px" valign="top" | |